-Search query
-Search result
Showing 1 - 50 of 144 items for (author: takahashi & m)
EMDB entry, No image
EMDB-44293:
Cryo-EM structure of MraY in complex with analogue 2
Method: single particle / : Hao A, Lee SY
EMDB entry, No image
EMDB-44294:
Cryo-EM structure of MraY in complex with analogue 3
Method: single particle / : Hao A, Lee SY
PDB-9b70:
Cryo-EM structure of MraY in complex with analogue 2
Method: single particle / : Hao A, Lee SY
PDB-9b71:
Cryo-EM structure of MraY in complex with analogue 3
Method: single particle / : Hao A, Lee SY
EMDB entry, No image
EMDB-36635:
Structure of arginine oxidase from Pseudomonas sp. TRU 7192
Method: single particle / : Yamaguchi H, Numoto N, Suzuki H, Nishikawa K, Kamegawa A, Takahashi K, Sugiki M, Fujiyoshi Y
PDB-8jt7:
Structure of arginine oxidase from Pseudomonas sp. TRU 7192
Method: single particle / : Yamaguchi H, Numoto N, Suzuki H, Nishikawa K, Kamegawa A, Takahashi K, Sugiki M, Fujiyoshi Y
EMDB-35411:
Dibekacin-bound E.coli 70S ribosome in the PURE system
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
EMDB-35412:
Arbekacin-bound E.coli 70S ribosome in the PURE system
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
EMDB-35413:
Dibekacin-added human 80S ribosome
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
EMDB-35414:
Arbekacin-added human 80S ribosome
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
PDB-8ifb:
Dibekacin-bound E.coli 70S ribosome in the PURE system
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
PDB-8ifc:
Arbekacin-bound E.coli 70S ribosome in the PURE system
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
PDB-8ifd:
Dibekacin-added human 80S ribosome
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
PDB-8ife:
Arbekacin-added human 80S ribosome
Method: single particle / : Tomono J, Asano K, Chiashi T, Tanaka Y, Yokoyama T
EMDB-34741:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-34742:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11 focused on RBD and NIV-11 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgl:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-8hgm:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-11
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33820:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 focused on RBD and NIV-8 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33821:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33822:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33823:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 focused on RBD and NIV-10 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33824:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33825:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33826:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-10 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33827:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 focused on RBD and NIV-13 interface
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33828:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 1)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33829:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33830:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-13 (state 3)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh6:
Structure of SARS-CoV-2 spike RBD in complex with neutralizing antibody NIV-8
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
PDB-7yh7:
SARS-CoV-2 spike in complex with neutralizing antibody NIV-8 (state 2)
Method: single particle / : Moriyama S, Anraku Y, Muranishi S, Adachi Y, Kuroda D, Higuchi Y, Kotaki R, Tonouchi K, Yumoto K, Suzuki T, Kita S, Someya T, Fukuhara H, Kuroda Y, Yamamoto T, Onodera T, Fukushi S, Maeda K, Nakamura-Uchiyama F, Hashiguchi T, Hoshino A, Maenaka K, Takahashi Y
EMDB-33643:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab816
Method: single particle / : Uchikubo T, Shirouzu M
EMDB-33644:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803
Method: single particle / : Uchikubo T, Shirouzu M
PDB-7y6l:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab816
Method: single particle / : Uchikubo T, Shirouzu M
PDB-7y6n:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab803
Method: single particle / : Uchikubo T, Shirouzu M
EMDB-33065:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765
Method: single particle / : Kamada K, Shirouzu M
EMDB-33066:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab712
Method: single particle / : Kamada K, Shirouzu M
EMDB-33067:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab709
Method: single particle / : Kamada K, Shirouzu M
EMDB-33068:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab847
Method: single particle / : Kamada K, Shirouzu M
PDB-7x93:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab765
Method: single particle / : Kamada K, Shirouzu M
PDB-7x94:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab712
Method: single particle / : Kamada K, Shirouzu M
PDB-7x95:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab709
Method: single particle / : Kamada K, Shirouzu M
PDB-7x96:
The SARS-CoV-2 receptor binding domain bound with the Fab fragment of a human neutralizing antibody Ab847
Method: single particle / : Kamada K, Shirouzu M
EMDB-27770:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 1
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
EMDB-27771:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 2
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
EMDB-27772:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 3
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
EMDB-27773:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 4
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
EMDB-27774:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 5
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
PDB-8dxn:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 1
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
PDB-8dxo:
Structure of LRRC8C-LRRC8A(IL125) Chimera, Class 2
Method: single particle / : Takahashi H, Yamada T, Denton JS, Strange K, Karakas E
Pages: